HUP0204005A2 - Pravastatin-nátrium új módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Pravastatin-nátrium új módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0204005A2
HUP0204005A2 HU0204005A HUP0204005A HUP0204005A2 HU P0204005 A2 HUP0204005 A2 HU P0204005A2 HU 0204005 A HU0204005 A HU 0204005A HU P0204005 A HUP0204005 A HU P0204005A HU P0204005 A2 HUP0204005 A2 HU P0204005A2
Authority
HU
Hungary
Prior art keywords
pravastatin sodium
preparation
pharmaceutical compositions
compositions containing
novel forms
Prior art date
Application number
HU0204005A
Other languages
English (en)
Inventor
Judith Aronhime
Vilmos Kéri
Árvai Edit Nagyné
Csaba Szabó
Original Assignee
BIOGAL Gyógyszergyár Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26866349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0204005(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BIOGAL Gyógyszergyár Rt. filed Critical BIOGAL Gyógyszergyár Rt.
Publication of HUP0204005A2 publication Critical patent/HUP0204005A2/hu
Publication of HUP0204005A3 publication Critical patent/HUP0204005A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya a pravastatin-nátrium új polimorf módosulatai. Azúj formák szelektíven kinyerhetők különböző protikus komponensttartalmazó oldószerrendszerekből oly módon, hogy a kristályosodásiarányt a hőmérséklettel kontrollálják. Az új polimorf formákhatóanyagként felhasználhatók a vérszérum koleszterinszintjénekcsökkentésére alkalmas gyógyszerkészítményekben. A találmány kiterjedaz új polimorf módosulatok előállítására és ezeket tartalmazógyógyszerkészítményekre is. Ó
HU0204005A 1999-12-14 2000-12-14 Novel forms of pravastatin sodium, process for their preparation and pharmaceutical compositions containing them HUP0204005A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17068599P 1999-12-14 1999-12-14
US19064900P 2000-03-20 2000-03-20
PCT/US2000/033867 WO2001043723A1 (en) 1999-12-14 2000-12-14 Novel forms of pravastatin sodium

Publications (2)

Publication Number Publication Date
HUP0204005A2 true HUP0204005A2 (hu) 2003-03-28
HUP0204005A3 HUP0204005A3 (en) 2003-05-28

Family

ID=26866349

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204005A HUP0204005A3 (en) 1999-12-14 2000-12-14 Novel forms of pravastatin sodium, process for their preparation and pharmaceutical compositions containing them

Country Status (15)

Country Link
US (3) US7001919B2 (hu)
EP (1) EP1242051A4 (hu)
JP (2) JP2003516959A (hu)
KR (1) KR20020062340A (hu)
CN (1) CN1434702A (hu)
AU (1) AU779306B2 (hu)
CA (1) CA2394200C (hu)
CZ (1) CZ20021998A3 (hu)
HK (1) HK1049441A1 (hu)
HU (1) HUP0204005A3 (hu)
IL (1) IL150187A0 (hu)
PL (1) PL364929A1 (hu)
SK (1) SK8312002A3 (hu)
WO (1) WO2001043723A1 (hu)
YU (1) YU45202A (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU779306B2 (en) * 1999-12-14 2005-01-13 Teva Gyogyszergyar Reszvenytarsasag Novel forms of pravastatin sodium
US7429588B2 (en) * 2001-03-27 2008-09-30 Dainippon Sumitomo Pharma Co., Ltd. Crystalline isoxazole derivative and medical preparation thereof
EP1737449A1 (en) * 2004-03-01 2007-01-03 LEK Pharmaceuticals D.D. Pharmaceutical composition
BRPI0514189A (pt) 2004-08-06 2008-06-03 Transform Pharmaceuticals Inc composições farmacêuticas de estatina e métodos de tratamento relacionados
CA2595635A1 (en) * 2005-02-09 2006-08-17 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Methods of making pravastatin sodium
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
CN101648867B (zh) * 2009-09-04 2012-07-11 天津大学 一种普伐他汀钠晶型及其制备方法和应用
EP2343054A1 (en) 2010-01-04 2011-07-13 LEK Pharmaceuticals d.d. Pellets and microparticles of pravastatin sodium and a process of making them
WO2012085191A1 (en) 2010-12-23 2012-06-28 Dsm Sinochem Pharmaceuticals Netherlands B.V. Crystalline form of pravastatine and process for the preparation thereof
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
CN105949062B (zh) * 2016-06-24 2017-06-13 广东蓝宝制药有限公司 一种规模化制备普伐他汀钠d型晶体的工艺
CN111018714B (zh) * 2019-12-27 2020-09-04 广东蓝宝制药有限公司 一种获得高纯a晶型普伐他汀钠的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) * 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
DE3682557D1 (de) * 1985-09-13 1992-01-02 Sankyo Co Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4857522A (en) * 1988-03-21 1989-08-15 E. R. Squibb & Sons, Inc. Derivatives of pravastatin for inhibiting cholesterol biosynthesis
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5099035A (en) * 1989-02-27 1992-03-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
US5157025A (en) 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
NZ250609A (en) 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
SI9300303A (en) * 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
IL112639A0 (en) 1994-03-11 1995-05-26 Bristol Myers Squibb Co A pharmaceutical composition containing pravastin
US5616595A (en) * 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
US5942423A (en) * 1995-06-07 1999-08-24 Massachusetts Institute Of Technology Conversion of compactin to pravastatin by actinomadura
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6165757A (en) 1997-02-20 2000-12-26 Dsm N.V. Nitrogen feed in statin fermentation
KR100210482B1 (ko) * 1997-04-10 1999-07-15 김종인 스트렙토마이세스엑스포리아투스(streptomycesexfoliatus)yj-118과이를이용한프라바스타틴나트륨의제조방법
EP1015600A1 (en) 1997-08-22 2000-07-05 Dsm N.V. Statin production by fermentation
SI9800046A (sl) 1998-02-18 1999-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SI20072A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
WO2000033821A1 (en) * 1998-12-07 2000-06-15 Bristol-Myers Squibb Company Enteric coated pravastatin bead formulation
US6682913B1 (en) * 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
MXPA01007807A (es) 1999-02-03 2003-06-04 Inst Drug Res Ltd Proceso microbiano para preparar pravastatina.
HUP9902352A1 (hu) 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
JP3881240B2 (ja) * 1999-11-30 2007-02-14 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 醗酵ブロスからスタチン化合物を回収するための方法
AU779306B2 (en) * 1999-12-14 2005-01-13 Teva Gyogyszergyar Reszvenytarsasag Novel forms of pravastatin sodium
CN1468098A (zh) 2000-10-05 2004-01-14 �ݰ¸Ƕ�ҩ�����޹�˾ 基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物
DE10209305A1 (de) 2001-04-30 2002-10-31 Basf Ag Thermische Spaltung von Allophanaten

Also Published As

Publication number Publication date
CA2394200C (en) 2006-10-03
HUP0204005A3 (en) 2003-05-28
US7262218B2 (en) 2007-08-28
EP1242051A4 (en) 2004-05-12
SK8312002A3 (en) 2003-05-02
AU779306B2 (en) 2005-01-13
CZ20021998A3 (cs) 2003-02-12
US7001919B2 (en) 2006-02-21
KR20020062340A (ko) 2002-07-25
YU45202A (sh) 2005-11-28
US20070197633A1 (en) 2007-08-23
AU2098701A (en) 2001-06-25
PL364929A1 (en) 2004-12-27
US20010041809A1 (en) 2001-11-15
JP2003516959A (ja) 2003-05-20
JP2005120105A (ja) 2005-05-12
CA2394200A1 (en) 2001-06-21
CN1434702A (zh) 2003-08-06
WO2001043723A1 (en) 2001-06-21
HK1049441A1 (zh) 2003-05-16
EP1242051A1 (en) 2002-09-25
IL150187A0 (en) 2002-12-01
US20050288370A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
ATE429210T1 (de) Orale flüssige zusammensetzungen
ATE255589T1 (de) Kristallin form i von clarithromycin
HUP0203257A2 (hu) Atorvastatin kalcium polimorf módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0204005A2 (hu) Pravastatin-nátrium új módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
FR2822826B1 (fr) Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HUP0100562A2 (hu) Szferoidok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
NO20015226L (no) Tri-aryl syrederivater som PPAR reseptor ligander, farmasoytisk sammensetning omfattende samme og anvendelse av samme for fremstilling av medikament.
DE69104991D1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
DK0973408T3 (da) Spiseis med bløde tilsætninger
IS4226A (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
HUP0402043A2 (hu) Rimonabant polimorf formája, eljárás ezen forma előállítására és ilyen polimorf formát tartalmazó gyógyászati készítmények
HUP0200580A2 (hu) Celecoxib polimorf kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
AU4949800A (en) 2-arylpurine-9-acetamide derivatives, process for the preparation thereof, medicinal compositions containing the same and intermediates of the derivatives
AU2705588A (en) New ciclosporin crystal form, processes for its production, pharmaceutical compositions containing it and its use.
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
AU5835400A (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and process for the preparation of the active substance
AU2841199A (en) Novel bis-benzamide derivatives, method for making same pharmaceutical compositions containing them and use thereof as medicine
CA2236641A1 (en) Preparation of fagopyritols and uses therefor
WO2004007441A3 (fr) Derives de 4,4' -dithiobis- (3-aminobutane-1-sulfonates) nouveaux et compositions les contenant
WO2003065991A3 (en) N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
RU94000064A (ru) Новые 2-циано-3-гидроксипропенамиды, метод их получения и содержащие их фармацевтические композиции
HUP0100019A2 (hu) A cipamfillin új polimorf formái, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
MA26698A1 (fr) Composition pharmaceutique concentree liquide de sertraline et procede pour sa preparation
EP0386920A3 (en) 2-hydroxy-3-thienyloxypropylamino derivatives
AP9801417A0 (en) Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders.

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: TEVA GYOGYSZERGYAR ZARTKOERUEEN MUEKOEDOE RESZ, HU

Free format text: FORMER OWNER(S): BIOGAL GYOGYSZERGYAR RT., HU